Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alimera Sciences Inc.
Pilot Study to Assess Safety and Efficacy of Medidur FA in AMD Patients Treated With Lucentis
May 23rd, 2008
Alimera Sciences Inc., a privately held ophthalmic pharmaceutical company announced that enrollment has begun for a pilot study to assess the safety and efficacy of Medidur FA in conjunction with Lucentis(R) (ranibizumab injection, Genentech) in patients with exudative age-related macular degeneration (wet AMD). This pilot study, which will be performed under an investigator sponsored IND, will compare two doses of Medidur FA (0.2 and 0.5 ug/day) in patients who have been treated with Lucentis for at least six months. The change from baseline in parameters such as visual acuity and retinal thickness will be assessed, in addition to comparing the number of Lucentis...
Source: Health Business Week (2008-05-23)
|
